Company news
Pyc Therapeutics Limited (ASX:PYC) news
Pyc Therapeutics Limited news releases on 6ix. Latest, Oct 14, 2024: Notice of Annual General Meeting/Proxy Form
Press releases — page 2
Notice of Annual General Meeting/Proxy Form
October 14, 2024
FDA Grants Rare Pediatric Disease Designation to PYC-001
August 29, 2024
Appendix 4E and Audited Financial Statements
August 29, 2024
PYC to Start Human Trials in Second Blinding Eye Disease
August 14, 2024
Visual Improvement in Multiple RP11 Patients
August 11, 2024
RP11 Clinical Trial Update - Amended
August 5, 2024
RP11 Clinical Trial Update
August 4, 2024
Extension of RP11 Single Dose Study Into Multiple Dose Study
July 22, 2024
Initial Dosing Completed in Cohort 1 of RP11 MAD Study
July 16, 2024
Commencement of RP11 Multiple Dose Trial
July 9, 2024
RP11 Drug Candidate Safe and Well Tolerated
June 30, 2024
PMS Drug Candidate Effective In Human Brain Cells
June 6, 2024
RP11 Clinical Trial Dosing Completed in Cohort 4
May 15, 2024
Successful GLP Tox Studies in Second Blinding Eye Disease
May 13, 2024
Presentation of RP11 Clinical Trial Data at ARVO Conference
May 5, 2024
RP11 Drug Candidate Progressing to Mid-Stage Human Trials
April 28, 2024
Kidney Disease Drug Candidate Progressing to Human Trials
April 21, 2024
$74.6 Million Extension of Cash Runway
April 10, 2024
PYC Equity Raising to Raise up to $74.6 Million
March 13, 2024
RP11 Clinical Trial - Dosing Completed in Cohort 3
February 27, 2024
Receipt of $4.5m Collaboration Fee
February 16, 2024
AI Driven Drug Discovery Collaboration with Google Cloud
January 1, 2024
RP11 Clinical Trial Progressing To High Dose Cohort
December 17, 2023
Response to Price Query
November 30, 2023
Supplementary Information
November 16, 2023
New Drug For Major Kidney Disease Effective In Human Models
November 12, 2023
PYC and FDA Align On Clinical Trial Pathway in ADOA
November 5, 2023
RP11 Clinical Trial Dosing Completed In Patient Cohort 2
November 2, 2023
PYC-001 Effective In Both NHPs and Patient-Derived Models
October 3, 2023
Safety Review Committee Approves Dose Escalation
September 21, 2023
RP11 Clinical Trial Dosing Completed In Patient Cohort 1
August 17, 2023
PYC Increases Ownership of VP-001 Program
August 9, 2023
PYC Receives FDA Fast Track Designation
August 1, 2023
Successful Toxicology Results Pave Way for Phase 2 Trial
July 17, 2023
FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL
June 29, 2023
Placement Supporting Document
May 11, 2023
Successful Completion of $30m Placement
May 10, 2023
Commencement of First Clinical Study in RP11
April 25, 2023
Second Drug Program Progressing to Human Trials
April 3, 2023
FDA Clears PYC to Commence First Human Trials in RP11
March 5, 2023
VP-001 IND Lodgement
February 1, 2023
Successful Toxicology Studies Pave Way for Human Trials
November 6, 2022
Central Nervous System Drug Program Added to PYC Pipeline
September 26, 2022
Preliminary Final Report
August 30, 2022
PYC Increases Shareholding in Vision Pharma
February 16, 2022
Quarterly Activities and Appendix 4C Cash Flow Report
January 26, 2022
Successful Completion of Key Translational Milestone
November 15, 2021
Retina Target Engagement Confirmed in Large Eye
September 29, 2021
Second Drug Program Progressing Towards Human Trials
June 8, 2021
March 2021 Quarterly Report and Cashflow
April 29, 2021